The FDA has started a review of GSK’s five-in-one meningococcal vaccine, cueing up a decision in mid-February next year, as it tries to chase down a rival candidate from Pfizer cleared last year. The ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback